FR 208419

Drug Profile

FR 208419

Alternative Names: FR 202893 (as racemic); FR 208418 (as S-enantiomer)

Latest Information Update: 18 Jul 2002

Price : $50

At a glance

  • Originator Fujisawa
  • Developer Fujisawa; Nippon Shokubai
  • Class Gastrokinetics
  • Mechanism of Action Cholecystokinin A receptor antagonists; Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Gastrointestinal disorders

Most Recent Events

  • 16 Jul 1998 Preclinical development for Gastrointestinal disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top